---
title: "Garden Biopharmaceutical issued a preliminary increase, with a net profit of 300 million to 350 million yuan for the fiscal year 2024, an increase of 55.97% to 81.96%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/224765182.md"
description: "Garden Biopharmaceutical released its performance forecast for 2024, expecting a net profit of 300 million to 350 million yuan, a year-on-year increase of 55.97%-81.96%. Due to the rise in selling prices of vitamin D3 products and the launch of new vitamin A series products, the company's operating revenue is expected to increase by approximately 13%, and the total gross profit is expected to rise by about 10%. The operating revenue and total gross profit of the vitamin segment are expected to increase by approximately 55% and 77%, respectively"
datetime: "2025-01-13T12:03:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/224765182.md)
  - [en](https://longbridge.com/en/news/224765182.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/224765182.md)
generator: "portal-rs"
---

# Garden Biopharmaceutical issued a preliminary increase, with a net profit of 300 million to 350 million yuan for the fiscal year 2024, an increase of 55.97% to 81.96%

According to the Zhitong Finance APP, Garden Biopharmaceutical (300401.SZ) released its performance forecast for 2024, expecting a net profit attributable to shareholders of the listed company to be between 300 million and 350 million yuan, a year-on-year increase of 55.97%-81.96%.

During the reporting period, influenced by the increase in the selling price of Vitamin D3 products and the launch of new Vitamin A series products, the company's operating revenue rose by approximately 13%, and the total gross profit increased by about 10%. Among them, the operating revenue of the vitamin segment increased by approximately 55%, and the total gross profit rose by about 77%

### Related Stocks

- [300401.CN](https://longbridge.com/en/quote/300401.CN.md)
- [603235.CN](https://longbridge.com/en/quote/603235.CN.md)
- [002001.CN](https://longbridge.com/en/quote/002001.CN.md)
- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)

## Related News & Research

- [08:10 ETTruvant Acquires New Jersey-Based Multi-Pak Packaging, a Specialist in Vitamins, Supplements and OTC](https://longbridge.com/en/news/296912238.md)
- [BYD to launch Sealion 08 on September 2 as Ocean lineup's flagship SUV](https://longbridge.com/en/news/296891117.md)
- [Lytix says FDA clears Phase III trial plan for ruxotemitide plus pembrolizumab in high-risk melanoma](https://longbridge.com/en/news/297124839.md)
- [Cerro de Pasco Resources publishes FY2026 annual report](https://longbridge.com/en/news/296917802.md)
- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**